Since its successful completion in 2003, there have been extraordinary advances in genome sequencing technology. In spite of being aware of the astonishing complexity of the genome architecture which has nothing but maximised our medical progress, we still lag in time when it comes to the diagnosis of rare diseases/disorders which takes several years.
Centogene is a German biotech company that already is partners with several important companies in the rare-diseases diagnosis space. It has now further collaborating with yet another company in this space, the US-based FDNA to support the latters’ comprehensive database that combines phenotypic and genomic information which is associated with over 8,000 rare diseases and genetic disorders. The German organization presently commands the largest mutation database for rare diseases which consists of data from approximately 125,000 individuals from over 110 countries, allowing the biotech to gain global insights into the epidemiological basis of hereditary disorders.
“There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases. This creates a tremendous market opportunity for us.” said Arndt Rolfs, CEO and Founder of Centogene at a press conference.
Centogene which is at an advantageous position currently, growing over a Compound Annual Growth
Rate (CAGR) of more than 40% has now raised a massive €25M in a series A round of funding to help boost the company’s growth and expansion plans, as a result, enabling it to broaden its portfolio involving biomarkers, diagnostic tests, and tools for oncogenetics. This amount of funding is not exactly small-scale and proves that the UK is finally ready to compete with the US in fundraising.It is indeed a huge amount of money (as mentioned several times before) going into an extremely important cause which we hope delivers what it intends to offer.
